Сравнение

Linaclotid vs. Pasireotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

851199-59-2

396091-73-9

Молекулярная масса

1526.74 g/mol

1047.21 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Linaclotid	Pasireotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Linaclotid and Pasireotid?: Linaclotid is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Linaclotid or Pasireotid?: The highest available evidence level is "РКИ на людях" for Linaclotid and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Linaclotid and Pasireotid in Germany and the United States?: Германия: Linaclotid — Рецептурный, Pasireotid — Рецептурный. США: Linaclotid — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Linaclotid

Pasireotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Linaclotid and Pasireotid?

Linaclotid is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Linaclotid or Pasireotid?

The highest available evidence level is "РКИ на людях" for Linaclotid and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Linaclotid and Pasireotid in Germany and the United States?

Германия: Linaclotid — Рецептурный, Pasireotid — Рецептурный. США: Linaclotid — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.